DDInter1298 DDInter1763
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Nisoldipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nisoldipine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Nisoldipine {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Nisoldipine {u} (Compound) downregulates {v} (Gene) NVL
NVL {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Nisoldipine {u} (Compound) downregulates {v} (Gene) GTF2A2
GTF2A2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Nisoldipine {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Nisoldipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nisoldipine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nisoldipine {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nisoldipine {u} (Compound) downregulates {v} (Gene) NVL
NVL {u} (Gene) regulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Nisoldipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Nisoldipine (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Temsirolimus (Compound)
Nisoldipine (Compound) downregulates NVL (Gene) and NVL (Gene) is upregulated by Temsirolimus (Compound)
Nisoldipine (Compound) downregulates GTF2A2 (Gene) and GTF2A2 (Gene) is downregulated by Temsirolimus (Compound)
Nisoldipine (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Nisoldipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Nisoldipine (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Nisoldipine (Compound) downregulates NVL (Gene) and NVL (Gene) regulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Temsirolimus (Compound)